Lynch Syndrome Center Conference: Identification & Management of Lynch Syndrome in Clinical Practice
Hosted by Dana-Farber Cancer Institute’s Lynch Syndrome Center, our first provider conference will be held virtually on Saturday, September 24, 2022 at 8:00 a.m. This conference will provide credit and is intended for physicians, physician assistants,
nurse practitioners, nurses, and genetic counselors from a diverse array of specialties, including oncology, gastroenterology, primary care, OBGYN, and surgery. This conference will educate attendees on state-of-the-art approaches to managing
individuals with known or suspected Lynch syndrome, a common, inherited form of cancer predisposition. Topics covered in this conference will include details about identifying and diagnosing Lynch syndrome in routine practice, endoscopic management
of individuals with Lynch syndrome, gynecologic care and risk reduction, as well as immune-based cancer prevention strategies.
For more information and to register, please visit Dana-Farber Cancer Institute's Lynch Syndrome Center Conference: Identification
& Management of Lynch Syndrome in Clinical Practice.
For questions, please email us at LynchSyndromeCenter@dfci.harvard.edu.
When to Refer a Patient
If your patient has a family history of multiple people on the same side of the family diagnosed with colorectal cancer, uterine cancer, ovarian cancer, or other Lynch syndrome-associated cancers, especially at a young age, please refer the patient to
our Lynch Syndrome Center.
Sapna Syngal, MD, MPH, and colleagues have developed a novel tool called the PREMM5 model (PREdiction Model
for gene Mutations) to identify individuals who have Lynch syndrome. The simple computerized personal and family history questionnaire uses a clinical prediction algorithm that estimates the cumulative probability of an individual
carrying a germline mutation in the MLH1, MSH2, MSH6, PMS2, or EPCAM genes. Mutations in these genes cause Lynch syndrome.
In addition to information about the individual being evaluated, the model requires:
- A personal or family history of colorectal cancer, endometrial (uterine) cancer, or other Lynch syndrome-associated cancers
- Types of cancer and ages at diagnosis of first-degree relatives from the affected side of the family (parents, siblings, children)
- Types of cancer and ages at diagnosis of second-degree relatives from the affected side of the family (grandparents, grandchildren, aunts, uncles, nieces, nephews)
Anyone who has a score of ≥ 2.5 percent should be evaluated for Lynch syndrome. This may include tumor testing via microsatellite instability (MSI) or mismatch repair immunohistochemistry (MMR IHC), genetic counseling, and/or germline
genetic testing. The current PREMM5 model is geared towards health care providers, but future directions include development of a patient-driven version so that individuals can assess their own risk.
How to Refer a Patient
A patient's primary care physician or community specialist is an integral part of the patient's care team. We are committed to working with you in the long-term care of your patient with Lynch syndrome.
Find out more about how to refer a patient to our Center. Note: When selecting the "Diagnosis," choose the "Lynch syndrome" option under the "Cancer Risk and Prevention (Adult)" option.
Support for Providers
- Our staff is willing to travel to your clinic or hospital to deliver educational talks or attend tumor boards to lend expertise. Please
get in touch if this would be helpful for your practice.
- We hold a monthly patient review via teleconference to review management recommendations for individual cases. If you would like to join to learn about the best management strategies on a case-by-case basis, please contact us.
- Certain individual cases may also be reviewed as a virtual consultation through Dana-Farber's Grand Rounds service. Please
contact us to learn more.
Support for Genetic Counselors
For genetic counselors following patients with Lynch Syndrome without a gastrointestinal oncologist or gastroenterologist to aid with medical management recommendations, please contact us to ensure your patients are receiving the most up-to-date and optimal care.
Lynch Syndrome Clinical Trials